Phenotypes associated with this allele

• Allele Symbol: Slc6a14^tm1Gana
• Allele Name: targeted mutation 1, Vadivel Ganapathy
• Allele ID: MGI:5788552
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Slc6a14^tm1Gana/Slc6a14^tm1Gana	Not Specified	MGI:5807360
cx2	Slc6a14^tm1Gana/Slc6a14^tm1Gana Tg(MMTVneu)202Mul/0	involves: FVB/N	MGI:5807362
cx3	Slc6a14^tm1Gana/Slc6a14^tm1Gana Tg(MMTV-PyVT)634Mul/0	Not Specified	MGI:5807361
ot4	Slc6a14^tm1Gana/Y	Not Specified	MGI:5807359

Genotype
MGI:5807360

hm1

• Allelic Composition: Slc6a14^tm1Gana/Slc6a14^tm1Gana
• Genetic Background: Not Specified

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:226105 )

♀N • homozygous females are viable and overtly normal with no significant alterations in plasma amino acid levels relative to wild-type controls

abnormal circulating cytokine level ( J:226105 )

♀ • plasma levels of GM-CSF (granulocyte macrophage colony-stimulating factor) are significantly increased relative to wild-type controls

♀ • however, no major changes are detected in most of the cytokines analyzed

abnormal circulating chemokine level ( J:226105 )

♀ • plasma levels of CCL5 (aka RANTES, regulated on activation, normal T cell expressed and secreted) are significantly decreased

decreased circulating interleukin-1 alpha level ( J:226105 )

♀ • plasma levels of IL-1alpha are significantly decreased

decreased circulating interleukin-4 level ( J:226105 )

♀ • plasma levels of IL-4 are significantly decreased

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:226105 )

♀N • virgin homozygous females exhibit normal mammary gland morphology and development

immune system

abnormal circulating cytokine level ( J:226105 )

♀ • plasma levels of GM-CSF (granulocyte macrophage colony-stimulating factor) are significantly increased relative to wild-type controls

♀ • however, no major changes are detected in most of the cytokines analyzed

abnormal circulating chemokine level ( J:226105 )

♀ • plasma levels of CCL5 (aka RANTES, regulated on activation, normal T cell expressed and secreted) are significantly decreased

decreased circulating interleukin-1 alpha level ( J:226105 )

♀ • plasma levels of IL-1alpha are significantly decreased

decreased circulating interleukin-4 level ( J:226105 )

♀ • plasma levels of IL-4 are significantly decreased

Genotype
MGI:5807362

cx2

• Allelic Composition: Slc6a14^tm1Gana/Slc6a14^tm1Gana; Tg(MMTVneu)202Mul/0
• Genetic Background: involves: FVB/N

neoplasm

decreased mammary gland tumor incidence ( J:226105 )

♀ • at 10 months of age, the % of mice with palpable mammary tumors is significantly lower than that in age-matched mice carrying the transgene on a wild-type background

decreased tumor growth/size ( J:226105 )

♀ • at 15 months of age, mice show a significant decrease in mammary tumor volume relative to age-matched mice carrying the transgene on a wild-type background

increased tumor latency ( J:226105 )

♀ • mice develop the first palpable mammary tumor at ~500 days, i.e. significantly later than mice carrying the transgene on a wild-type background

endocrine/exocrine glands

decreased mammary gland tumor incidence ( J:226105 )

♀ • at 10 months of age, the % of mice with palpable mammary tumors is significantly lower than that in age-matched mice carrying the transgene on a wild-type background

integument

decreased mammary gland tumor incidence ( J:226105 )

♀ • at 10 months of age, the % of mice with palpable mammary tumors is significantly lower than that in age-matched mice carrying the transgene on a wild-type background

Genotype
MGI:5807361

cx3

• Allelic Composition: Slc6a14^tm1Gana/Slc6a14^tm1Gana; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: Not Specified

neoplasm

decreased metastatic potential ( J:226105 )

♀ • at 4 months of age, no metastatic nodules are detected in the lung, unlike in mice carrying the transgene on a wild-type background

decreased tumor growth/size ( J:226105 )

♀ • at 4 months of age, total mammary tumor volume is significantly lower than that in mice carrying the transgene on a wild-type background which exhibit tumor sizes of 2000-2500 mm³

♀ • decreased mammary tumor growth is associated with amino acid deficiency and a marked decrease in cell proliferation, mTOR phosphorylation, and HIF1alpha signaling

increased tumor latency ( J:226105 )

♀ • no mice develop mammary tumors at 3 months of age, whereas all mice carrying the transgene on a wild-type background start developing tumors in multiple mammary glands at ~72 days

♀ • small tumor nodules are, however, detectable at 4 months of age, indicating a significant delay in mammary tumor development

homeostasis/metabolism

abnormal amino acid level ( J:226105 )

♀ • mammary tumors exhibit amino acid starvation, as evidenced by the increased mRNA levels for asparagine synthetase (ASNS) and CHOP (CCAAT/enhancer-binding protein homologous protein), two genes that are responsive to changes in the amino acid nutritional status of cells

♀ • however, tumor tissues show no compensatory changes in mRNA expression of other amino acid transporters

immune system

abnormal immunoglobulin level ( J:226105 )

♀ • surprisingly, mammary tumors exhibit a marked upregulation of immunoglobulin genes, suggesting a boost in tumor immunity

hematopoietic system

abnormal immunoglobulin level ( J:226105 )

♀ • surprisingly, mammary tumors exhibit a marked upregulation of immunoglobulin genes, suggesting a boost in tumor immunity

Genotype
MGI:5807359

ot4

• Allelic Composition: Slc6a14^tm1Gana/Y
• Genetic Background: Not Specified

normal phenotype

no abnormal phenotype detected ( J:226105 )

♂N • hemizygous males are viable, fertile, and overtly normal